

vectura

31st Annual JP Morgan Healthcare Conference

January 7-10 2013

Disclaimer

This presentation has been organised by Vectura Group plc (the Company) in order to provide general information on the Company. This material has been prepared solely by the Company and is (i) for your private information, and the Company is not soliciting any action based upon it; (ii) not to be construed as an offer to sell or issue or a solicitation of an offer to buy or subscribe for any security and (iii) based upon information that the Company considers reliable. The Company does not represent that the information contained in this material is accurate or complete, and it should not be relied upon as such. No representation, warranty or undertaking, express or implied, is or will be made with respect to the fairness, accuracy or completeness of any of the information or statement of opinion or expectation contained herein or stated in the presentation or any other such information nor shall you be entitled to rely upon it. In furnishing you with this information no obligation is undertaken to provide you with any further information, to update this information nor any other information nor to correct any information contained herein or any omission therefrom.
The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933 (as amended), and may not be offered or sold in the United States or to U.S. persons unless they have been registered under such Act, or except in compliance with an exemption from or in a transaction not subject to the registration requirements of such Act.

The Company's securities have not been approved or disapproved by the US Securities and Exchange Commission, any state securities commission in the United States or any other regulatory authority in the United States, nor have any of the foregoing authorities passed on or endorsed the merits of the institutional placing described in this material or the accuracy or adequacy of the information contained in this material. Any representation to the contrary is a criminal offence in the United States.

This material does constitute or form part of any offer or invitation to sell or issue or any solicitation of an offer to acquire, purchase or subscribe for the Company's securities in any jurisdiction in which such an offer, invitation or solicitation is unlawful.
No part of this material may be (i) copied, photocopied, or duplicated in any form, by any means, or (ii) redistributed, published, or disclosed by recipients to any other person, in each case without the Company's prior written consent. This material is only being provided to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 or any order made thereunder or to other persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, who are QIBs or Institutional Accredited Investors, or who are otherwise permitted by law to receive it.

In relation to information about the price at which securities in the Company have been bought or sold in the past, note that past performance cannot be relied upon as a guide to future performance. In addition, certain statements, beliefs and opinions in this document, are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements . These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. The occurrence of some of the events described in this document and the presentation that will be made, and the achievement of the intended results, are subject to the future occurrence of many events, some or all of which are not predictable or within the Company's control; therefore, actual results may differ materially from those anticipated in any forward looking statements. The Company disclaims any obligation to update these forward looking statements.

By attending the presentation to which this document relates or by accepting this document you will be taken to have represented, warranted and undertaken that: (i) you are a person falling within one or more of the categories referred to above as being permitted to receive this presentation; (ii) you have read and agree to comply with the contents of this disclaimer notice; and (iii) you will not at any time have any discussion, correspondence or contact concerning the information in this document with any of the directors or employees of the Company, its subsidiaries nor with any of their suppliers, customers, sub contractors or any governmental or regulatory body without the prior written consent of the Company.

Vectura Today

Leading developer of inhaled pharmaceuticals

- Two late-stage products, partnered with Novartis, in development for COPD
  - NVA 237 (US) & QVA149 (EU/Japan/RoW/US)
  - Comprehensive development programme driven and fully funded by Novartis
- Approved product (Seebri® Breezhaler®), for COPD in EU & Japan/RoW
  - Marketed by Novartis

Three generic respiratory programmes

- VR315 - Licensed in EU/RoW (Sandoz) and in US (undisclosed partner)
- VR506 - Development ongoing to generate licensing package
- VR632 - Licensed in EU (Sandoz)

Technology platforms, validated by deals, underpin product focus

- Number two globally in respiratory patent filings (DPI technology & formulation)
- “Big Pharma” validation e.g. current deals with Novartis, Sandoz and GSK

Strong balance sheet with £72.1m in cash

- Supported by existing royalty streams and a disciplined approach to cost control

Significant Respiratory Market Opportunity



Asthma/COPD market estimated at $29bn in 2010 growing to $47bn by 2017

Source: Sell side analyst reports; BCC Research (2012)

COPD Treatment Landscape Today

- **Three major COPD drugs drive current sales of ca. $10bn**
  - Advair®/Seretide® (ICS/LABA combination) $3.5bn COPD sales in 2011
  - Symbicort® (ICS/LABA combination) $1.2bn COPD sales in 2011
  - Spiriva® (LAMA) $4.4bn COPD sales in 2011
- **Treated according to GOLD guidelines**
  - 2011 update classifies patients according to two key attributes:
    - Symptoms
    - Exacerbation risk
- **Current inhaled therapies**
  - Bronchodilators
    - Long acting muscarinic antagonists (LAMA)
    - Short/long acting beta agonists (SABA/LABA)
  - Inhaled corticosteroids (ICS)

Changing Market Dynamics to Benefit Vectura

- **Single LAMA products to remain an important product class (NVA237)[1]**
  - ~ 30% volume share within 7 years
  - Upside opportunity from use of LAMAs in asthma
    - Encouraging exacerbation data in severe asthmatics using Spiriva (ERS 2012)
- **LAMA/LABA combinations will redefine the standard of care in COPD (QVA149)**
  - The combination is synergistic over its components
  - Combination products expected to alter market dynamics[1]
- **Conclusion: Vectura is poised to capture significant value**
  - Seebri® Breezhaler®
  - QVA149
  - Generic products

[1]*Source: Sell-side analyst research*

Seebri® Breezhaler® (glycopyrronium bromide, NVA237)

- **Once-daily maintenance bronchodilator treatment for COPD licensed to Novartis**
- ***Seebri® Breezhaler®* approved in EU, Japan, Australia & Canada**
  - US filing expected Q1 2014
- **Comprehensive Phase III clinical trial programme**
  - Being undertaken by Novartis
- **Market roll out is underway**
  - Launched in Germany, UK & Japan by Novartis

QVA149 – Once-daily, Fixed-dose LAMA/LABA Combination

- **Significantly derisked: component drugs and device already approved for COPD**
  - Indacaterol maleate - Onbrez® Breezhaler®
  - Glycopyrronium bromide - Seebri® Breezhaler®
- **Regulatory filing recently submitted by Novartis in EU (Oct. 2012)**
  - Japan regulatory filing submitted by Novartis in November 2012
- **Novartis expected to file in US by end 2014**
- **Comprehensive COPD registration trial programme undertaken by Novartis (IGNITE)**
  - > 7,000 patients across 42 countries
  - Significant improvements over
    - Placebo
    - Tiotropium bromide
    - Salmeterol/fluticasone
    - Individual components

Respiratory Generics – Vectura's Franchise

GyroHaler® - competitive product design



- Performance engineered to match brand-leaders
- Easy to use
- Inexpensive, minimalist design
- Accurate, reproducible dosing through excellent protection of the powder formulation

Focus on promising, high value products

- VR315 - Licensed in EU/RoW (Sandoz) and in US (undisclosed partner)
- VR506 - Development ongoing, strong out-licensing candidate
- VR632 - Licensed in EU (Sandoz)

Comprehensive understanding of complex regulatory requirements

- Significant experience of interaction with regulators, particularly the EMA and FDA

Success Factors Underpinning our Product Development









EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

FDA

MHRA

gsk GlaxoSmithKline

Boehringer Ingelheim

NOVARTIS

SANDOZ

Significant IP Generation within DPI Space



Monetising Vectura's IP

Examples of Vectura IP deals

Boehringer Ingelheim (April 2006)

- Worldwide collaboration, development and licence agreement



GSK (August 2010)

- Licensing of Vectura's drug formulation patents in relation to two late stage development compounds



No additional investment required to generate these returns

Vectura invests approx. £3m per annum on its patent portfolio

Attractive returns from IP portfolio and know-how

Financial Highlights

- **Strong cash balance of £72.1m**
- **Supported by recurring revenue**
- **Prudent approach to overall cost management**

£m	H1 2012/13	H1 2011/12	FY 2011/12
Revenues	17.0	21.1	33.0
Gross profit	16.9	19.7	30.8
EBITDA	2.6	4.9	(4.2)
Profit/(loss) after tax	0.9	2.6	(4.4)
Cash	**72.1**	**80.2**	**75.5**

Anticipated Near-term Catalysts

NVA237	QVA149	VR315	VR632	VR506
EU & Japan approval & launch ✓	EU & Japan filing ✓	US development milestones ✓	Further development progress	Clinical progress
Filing in US	Approvals in Europe & RoW	Further development milestones	Approval in Europe	Out-licensing and approval
Approval in US	Approval in Japan	Approvals in Europe & RoW	Licensing for other territories	
	Filing & approval in US	Approval in US		

Summary & Outlook

- **Significant clinical and regulatory success with key branded programmes**
  - Driven by Novartis
  - First launches of Seebri® Breezhaler® are now underway
  - QVA149 filed for approval in Europe and Japan
- **Generic programmes continue to make progress**
- **Robust financial position**
  - Supplemented by multiple royalty streams and additional milestones
  - Tight cash control through product development prioritisation
- **Future strategy will continue to focus on value creation in a prudent manner**
  - Products assessed on suitability to add value
    - Strategy does not envisage spend on highly attritional discovery projects
  - Emerging market opportunities may be suitable for “value brand” offering
    - Local strategies with local players are key